Gentian Diagnostics ASA (Nasdaq Stockholm: GENT) reported a 14% year-over-year increase in Q2 FY 2025 sales to NOK 43.6 million, with strong momentum from the U.S. (+156%) and Asia (+43%). However, operational challenges and raw material issues drove gross margins down to 44%, resulting in an EBITDA of NOK 1.7 million and a net loss of NOK 1.96 million (–NOK 0.13/share). The company remains cash-positive with NOK 80 million and boasts an 85% equity ratio. Pipeline progress includes ongoing NT-proBNP assay development on schedule. The earnings call offers insights on commercial expansion, production stabilization, cost control, and future margin recovery.
📢 Disclaimer: This video includes segments from Gentian Diagnostics ASA’s Q2 2025 earnings call, used for educational purposes under fair use (Section 107, US Copyright Act). No affiliation or endorsement by Gentian Diagnostics is implied. All rights remain with Gentian Diagnostics ASA. For more information, visit . For inquiries, contact FyfullStore@gmail.com.
コメントを残す